Hydroxychloroquine trial was stopped because an academic published a paper stating hydroxychloroquine could lead to more deaths. That was considered bad news for GMV because I thought the emergency approval for GMV product was linked to Hydroxychloroquine . However, the journal has withdrawn the paper because he cannot verify the accuracy of the results. Global trials of hydroxychloroquine will recommence. This must be a very good news for GMV. That is how I read it.
- Forums
- ASX - By Stock
- Hydroxychloroquine study withdrawn - WHO restarts trials
Hydroxychloroquine trial was stopped because an academic...
-
- There are more pages in this discussion • 20 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add GMV (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
1CG
ONE CLICK GROUP LIMITED
Mark Waller, MD
Mark Waller
MD
Previous Video
Next Video
SPONSORED BY The Market Online